Saturday 28 May 2022

Health authorizes sale of treatment against Covid-19 Covid-19 in nonhospitalized patients

Costa Rica's Ministry of Health authorizes the sale of Molnupiravir from the pharmaceutical company Merck Sharp & Dohme

Paying the bills

Latest

CHEC will have eight more months to complete expansion of RUTA 32

QCOSTARICA - With fingers crossed, by February 2023, the...

Has Costa Rica reached the peak of the fifth wave due to Covid-19?

QCOSTARICA - Although the growth trend of diagnoses by...

Campaign against the seasonal influenza (flu) virus will start in June

QCOSTARICA - The Caja Costarricense de Seguro Social (CCSS)...

Is ¢700 colones to one dollar around the corner?

QCOSTARICA - The dollar exchange is expected to maintain...

Hospitalizations for covid-19 increased in the last week

QCOSTARICA - Covid-19 is still with us despite the...

Criminals prefer to steal cars with better gas mileage due to the increase in the price of gasoline

QCOSTARICA - As the country nears another record-setting increase...

UCR affirms that a strong intervention on the exchange rate is inconvenient

QCOSTARICA - The Institute for Research in Economic Sciences...

Dollar Exchange

¢675.89 Buy

¢685.03 small> Sell

28 May 2022 - At The Banks - BCCR

Paying the bills

Share

QCOSTARICA – The Ministry of Health notified Merck Sharp & Dohme on Wednesday of the emergency use authorization for the Molnupiravir 200 mg capsules, which enables the company to sell it in Costa Rica.

 

- Advertisement -

Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for the treatment of mild to moderate COVID-19 disease in adults with positive direct viral test results and who are at high risk of progression to severe COVID-19, including hospitalizations or death.

The New England Journal of Medicine concluded that early treatment with Molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.

Molnupiravir dose in adult patients is 800 mg (four 200 mg capsules) to be administered orally every 12 hours for 5 days, with or without food, and should be taken as soon as possible after a diagnosis of the Covid-19 infection.

The use authorization is provided based on the Administrative Resolution MS-DM-RM-1363-2022 published on January 24 of this year, which establishes the requirements to obtain an Authorization for the Use and Import of medicines to treat Covid-19. 19, based on the recognition of the Marketing Authorization or Emergency Use Authorization of Strict Regulatory Authorities or of medicines recommended by the World Health Organization.

As part of the authorization, Merck Sharp & Dohme must maintain records of the distribution of the medicine (ie, lot numbers, quantity, date and destination), as well as submit monthly reports of possible adverse or safety events.

When the medication will be on sale in Costa Rica or its cost is not yet known.

- Advertisement -

 

- Advertisement -
Paying the bills
Ricohttp://www.theqmedia.com
"Rico" is the crazy mind behind the Q media websites, a series of online magazines where everything is Q! In these times of new normal, stay at home. Stay safe. Stay healthy.

Related Articles

Has Costa Rica reached the peak of the fifth wave due to Covid-19?

QCOSTARICA - Although the growth trend of diagnoses by Covid-19 indicates...

Hospitalizations for covid-19 increased in the last week

QCOSTARICA - Covid-19 is still with us despite the relaxation of...

Subscribe to our stories

To be updated with all the latest news, offers and special announcements.